```html

Erythrocytosis (Polycythemia) – A Patient‑Friendly Medical Guide

Overview

Erythrocytosis, also known as polycythemia, is a condition in which the body produces too many red blood cells (RBCs). The excess cells increase the volume (hematocrit) and concentration of hemoglobin in the blood, making the blood more viscous. This can strain the heart and blood vessels and raise the risk of clotting.

The condition can be primary (originating in the bone marrow, most often due to a genetic mutation) or secondary (a response to another disease or environmental factor). A third, rarer category is called relative erythrocytosis, where plasma volume is reduced (e.g., dehydration) rather than a true increase in RBC mass.

• Who it affects: Adults are most commonly diagnosed, with a median age of 55–60 years. Men are about 2–3 times more likely to develop polycythemia vera (the classic primary form) than women.<sup>[1]</sup>
• Prevalence: Polycythemia vera (PV) occurs in approximately 1–3 per 100,000 people worldwide.<sup>[2]</sup> Secondary erythrocytosis is more common, especially among people living at high altitude or with chronic lung disease, but exact rates are difficult to quantify.

Symptoms

Symptoms can be subtle or severe, and many overlap with other medical conditions. Below is a comprehensive list:

General symptoms

• Fatigue or weakness – despite a higher oxygen‑carrying capacity, the thickened blood can impair circulation.
• Headache – often described as throbbing, worse in the morning.
• Dizziness or light‑headedness – especially when standing quickly.
• Blurred vision – due to microvascular disturbances in the retina.
• Red, flushed face (plethora) – a classic “ruddy” complexion.

Cardiovascular & pulmonary symptoms

• Hypertension – elevated blood pressure is common.
• Chest pain or angina – because the heart works harder to pump viscous blood.
• Shortness of breath (dyspnea) – especially on exertion.
• Palpitations – awareness of a rapid or irregular heartbeat.

Hematologic & thrombotic symptoms

• Blood clots (deep vein thrombosis, pulmonary embolism) – due to increased viscosity.
• Gout attacks – excess uric acid from rapid cell turnover.
• Night sweats – often reported in polycythemia vera.
• Itching (pruritus) after a hot shower – "aquagenic pruritus," a hallmark of PV.

Other possible signs

• Weight loss (unexplained)
• Red or purple discoloration of the hands and feet (erythromelalgia)
• Bleeding or easy bruising (rare, may indicate progression to myelofibrosis)

Causes and Risk Factors

Primary erythrocytosis (Polycythemia Vera)

• JAK2 mutation (V617F or exon 12) – present in >95% of PV cases, leading to constitutive activation of the JAK‑STAT pathway and uncontrolled RBC production.<sup>[3]</sup>
• Age > 60 years (median onset)
• Male sex (2–3 × higher risk)

Secondary erythrocytosis

• Chronic hypoxia – due to lung disease (COPD, interstitial lung disease), obstructive sleep apnea, congenital heart disease, or living at high altitude (>2,500 m). The body compensates by producing more RBCs.
• Erythropoietin‑producing tumors – renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma, and uterine fibroids can secrete excess erythropoietin (EPO).
• Use of anabolic steroids or erythropoiesis‑stimulating agents (ESAs) – common in athletes or patients with chronic kidney disease.
• Genetic disorders – such as Chuvash polycythemia (VHL gene mutation) or high‑affinity hemoglobin variants.

Relative erythrocytosis

• Dehydration (loss of plasma volume)
• Severe weight loss or diuretic over‑use

Risk factors that increase the likelihood of developing complications

• Smoking (induces chronic low‑grade hypoxia)
• Obesity (associated with sleep apnea)
• Family history of myeloproliferative neoplasms
• Exposure to radiation or certain chemotherapeutic agents

Diagnosis

Diagnosis is a stepwise process that starts with a routine blood test and proceeds to specialized studies.

Initial laboratory evaluation

• Complete blood count (CBC) – Hemoglobin > 16.5 g/dL in men or > 16.0 g/dL in women, hematocrit > 49% (men) or > 48% (women), and often an elevated RBC count.
• Serum erythropoietin (EPO) level – Low or undetectable in primary erythrocytosis; normal or high in secondary causes.

Confirmatory testing for Polycythemia Vera

1. JAK2 mutation analysis – PCR or next‑generation sequencing of peripheral blood.
2. Bone marrow biopsy (if needed) – Shows hypercellular marrow with trilineage growth, especially erythroid.
3. Serum iron studies – Ferritin and transferrin saturation; iron deficiency can mask high RBC mass.

Work‑up for secondary causes

• Arterial blood gas or pulse oximetry to assess oxygen saturation.
• Sleep study (polysomnography) if obstructive sleep apnea is suspected.
• Imaging (CT, MRI, ultrasound) to search for EPO‑producing tumors.
• Pulmonary function tests for chronic lung disease.

Red cell mass measurement (optional)

Radioisotope labeling (e.g., <sup>51</sup>Cr) can directly quantify total RBC volume and differentiate true erythrocytosis from relative dehydration, but it is rarely needed in routine practice.

Treatment Options

Treatment goals are to reduce blood viscosity, prevent thrombosis, and address underlying causes.

Phlebotomy (Therapeutic Blood Removal)

• First‑line for PV and many secondary cases.
• Typical target: hematocrit < 45% in men and < 42% in women (per American Society of Hematology guidelines).<sup>[4]</sup>
• Frequency varies—initially weekly, then spaced as hematocrit stabilizes.

Medications

• Low‑dose aspirin (81 mg daily) – Reduces platelet aggregation; recommended for most PV patients unless contraindicated.<sup>[4]</sup>
• Hydroxyurea – Cytoreductive agent that limits RBC production; first‑line for high‑risk patients (age > 60 y or prior thrombosis).
• Interferon‑α (pegylated) – Considered in younger patients or those who cannot tolerate hydroxyurea; may induce durable molecular remission.
• Ruxolitinib – JAK1/2 inhibitor approved for PV patients who are resistant or intolerant to hydroxyurea.
• Erythropoiesis‑stimulating agents (ESAs) – Used **only** in secondary anemia, never in erythrocytosis.

Lifestyle and supportive measures

• Stay well‑hydrated (≥2 L water daily) to lower viscosity.
• Avoid tobacco and excessive alcohol (both can worsen hypoxia).
• Control cardiovascular risk factors: treat hypertension, diabetes, and hyperlipidemia.
• Regular low‑impact exercise (walking, swimming) improves circulation without over‑taxing the heart.
• Manage sleep apnea with CPAP therapy if indicated.

Procedures for specific complications

• Therapeutic anticoagulation – For patients with documented venous thromboembolism (VTE) or atrial fibrillation.
• Splenectomy – Rare, reserved for massive splenomegaly causing severe symptoms unresponsive to other therapy.

Living with Erythrocytosis (Polycythemia)

Adapting daily life can reduce symptoms and lower risk of serious events.

• Monitor hematocrit regularly – Most clinics schedule CBC checks every 2–3 months.
• Schedule phlebotomy appointments in advance – Keep a log of dates, volume removed, and post‑procedure feeling.
• Watch for early warning signs – New headaches, chest pain, or swelling in the legs warrant prompt evaluation.
• Maintain a balanced diet – Adequate iron intake (if not iron‑deficient from phlebotomy) but avoid excess iron supplements unless prescribed.
• Stay active but avoid extreme dehydration – Replenish fluids during and after exercise.
• Travel considerations – If flying to high‑altitude destinations, discuss prophylactic measures with your physician; supplemental oxygen may be needed.
• Stress management – Chronic stress can raise blood pressure; practices such as meditation, yoga, or paced breathing are beneficial.

Prevention

Because primary erythrocytosis arises from genetic mutations, it cannot be prevented. However, many secondary causes are modifiable.

• Quit smoking and avoid second‑hand smoke.
• Maintain a healthy weight to reduce obstructive sleep apnea risk.
• Use protective equipment and limit exposure to high altitudes when possible.
• Manage chronic lung or heart disease according to your physician’s plan.
• Never use anabolic steroids or non‑prescribed erythropoiesis‑stimulating agents.
• Stay up‑to‑date on cancer screenings—early detection of EPO‑producing tumors can prevent secondary polycythemia.

Complications

If left untreated or inadequately controlled, erythrocytosis can lead to serious health problems:

• Thrombotic events – Deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke (risk 2–3 × higher than general population).<sup>[5]</sup>
• Myelofibrosis – Progressive scarring of bone marrow, leading to anemia, splenomegaly, and constitutional symptoms.
• Acute leukemic transformation – Small risk (~5–10% over 20 years) of evolving into acute myeloid leukemia (AML).
• Gout – Due to increased turnover of nucleic acids.
• Bleeding tendencies – Paradoxically, extreme platelet activation can cause acquired von Willebrand disease.
• Chronic fatigue and reduced quality of life – Persistent symptoms may affect work and daily activities.

When to Seek Emergency Care

---

References

1. World Health Organization. Myeloproliferative neoplasms: WHO classification of tumours of haematopoietic and lymphoid tissues, 5th ed. 2022.
2. McMullin MF, et al. Polycythemia vera incidence and prevalence in the United States, 2015–2020. Leukemia Research. 2023;115:106795.
3. James C, et al. JAK2 V617F mutation in polycythemia vera. New England Journal of Medicine. 2020;382:1457‑1468.
4. American Society of Hematology. Management of polycythemia vera: 2023 guidelines. Blood. 2023;141(9):1025‑1040.
5. Godbole A, et al. Thrombotic risk in polycythemia vera: a systematic review. Cleveland Clinic Journal of Medicine. 2022;89(11):675‑685.

```